Literature DB >> 11421580

Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E.

I Veinbergs1, E Van Uden, M Mallory, M Alford, C McGiffert, R DeTeresa, R Orlando, E Masliah.   

Abstract

Apolipoprotein E (apoE) is known to bind to at least five receptors, including the low-density lipoprotein (LDL) receptor-related protein (LRP), very low density LDL receptor (VLDL-R), LDL-R, apoE receptor 2 (apoER2), and megalin/gp330. In this context, the main objective of the present study was to better understand the contributions of LRP and LDL-R to the in vivo neurotrophic effects of apoE. For this purpose, apoE-deficient and receptor-associated protein (RAP)-deficient mice were infused with recombinant apoE3, RAP, or saline. Infusion of apoE3 into apoE-deficient mice resulted in amelioration of degenerative alterations of pyramidal neurons, but had no effect on somatostatin-producing interneurons. In contrast, infusion of apoE3 into RAP-deficient mice resulted in amelioration of degenerative alterations of somatostatin-producing interneurons. LRP and LDL-R levels were significantly reduced in RAP-deficient mice, but significantly increased in the apoE-deficient mice. In contrast, levels of apoE were reduced in the RAP-deficient mice compared to wildtype controls, suggesting that neurotrophic effects of apoE3 in the RAP-deficient mice were related to a combined deficit in endogenous apoE and selected apoE receptors. Furthermore, in apoE-deficient mice, infusion of apoE3 had a neurotrophic effect on somatostatin-producing interneurons only when combined with RAP, suggesting that increased expression of apoE receptors in apoE-deficient mice prevented apoE from rescuing somatostatin-producing neurons. This study supports the contention that some of the in vivo neurotrophic effects of apoE are mediated by LRP and LDL-R and that a critical balance between levels of apoE and its receptors is necessary for the differential neurotrophic effects to appear. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11421580     DOI: 10.1006/exnr.2001.7684

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

1.  Alpha-synuclein aggregation involves a bafilomycin A 1-sensitive autophagy pathway.

Authors:  Jochen Klucken; Anne-Maria Poehler; Darius Ebrahimi-Fakhari; Jacqueline Schneider; Silke Nuber; Edward Rockenstein; Ursula Schlötzer-Schrehardt; Bradley T Hyman; Pamela J McLean; Eliezer Masliah; Juergen Winkler
Journal:  Autophagy       Date:  2012-05-01       Impact factor: 16.016

2.  ApoE4 disrupts sterol and sphingolipid metabolism in Alzheimer's but not normal brain.

Authors:  Veera Venkata Ratnam Bandaru; Juan Troncoso; David Wheeler; Olga Pletnikova; Jessica Wang; Kathy Conant; Norman J Haughey
Journal:  Neurobiol Aging       Date:  2007-09-20       Impact factor: 4.673

3.  Polyamine pathway contributes to the pathogenesis of Parkinson disease.

Authors:  Nicole M Lewandowski; Shulin Ju; Miguel Verbitsky; Barbara Ross; Melissa L Geddie; Edward Rockenstein; Anthony Adame; Alim Muhammad; Jean Paul Vonsattel; Dagmar Ringe; Lucien Cote; Susan Lindquist; Eliezer Masliah; Gregory A Petsko; Karen Marder; Lorraine N Clark; Scott A Small
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

4.  HIV-1 Tat alters neuronal autophagy by modulating autophagosome fusion to the lysosome: implications for HIV-associated neurocognitive disorders.

Authors:  Jerel Fields; Wilmar Dumaop; Simona Eleuteri; Simona Elueteri; Sofia Campos; Elisabeth Serger; Margarita Trejo; Kori Kosberg; Anthony Adame; Brian Spencer; Edward Rockenstein; Johnny J He; Eliezer Masliah
Journal:  J Neurosci       Date:  2015-02-04       Impact factor: 6.167

5.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

6.  Differences in amyloid-β clearance across mouse and human blood-brain barrier models: kinetic analysis and mechanistic modeling.

Authors:  Hisham Qosa; Bilal S Abuasal; Ignacio A Romero; Babette Weksler; Pierre-Oliver Couraud; Jeffrey N Keller; Amal Kaddoumi
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

7.  Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy.

Authors:  Leslie Crews; Brian Spencer; Paula Desplats; Christina Patrick; Amy Paulino; Edward Rockenstein; Lawrence Hansen; Anthony Adame; Douglas Galasko; Eliezer Masliah
Journal:  PLoS One       Date:  2010-02-19       Impact factor: 3.240

8.  Type 3 Diabetes: Cross Talk between Differentially Regulated Proteins of Type 2 Diabetes Mellitus and Alzheimer's Disease.

Authors:  Khyati Mittal; Ruchi Jakhmola Mani; Deepshikha Pande Katare
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

9.  Receptor-associated protein (RAP) plays a central role in modulating Abeta deposition in APP/PS1 transgenic mice.

Authors:  Guilian Xu; Celeste Karch; Ning Li; Nianwei Lin; David Fromholt; Victoria Gonzales; David R Borchelt
Journal:  PLoS One       Date:  2008-09-08       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.